Lapatinib, known as a small-molecule kinase inhibitor, could target the EGFR gene and Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) gene, which was approved by the US Food and Drug Administration (FDA) in 2007 for the therapy of breast cancer patients.49 This evidence concerns the gene ERBB2 and breast cancer.